Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cidofovir Versus Best Supportive Care for BK Virus Related Hemorrhagic Cystitis
NCT01295645Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2011
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hemorrhagic cystitis (HC) comparing Standard of Care + Cidofovir with No Cidofovir (2 arms). Primary endpoint: Number of Patients with Microbiologic Response at 8 weeks. Started Mar 2011; status: active, not recruiting.
02
Drugs
cidofovir
03
Conditions
hemorrhagic cystitis (HC)
Beyond the preview
Go deeper on NCT01295645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01295645.